Schrödinger, Inc. 10-Kyear ended 2025-12-31

Executive Summary

Schrödinger grew FY2025 revenue 23%, led by Novartis collaboration work and expanding hosted-software sales, but higher delivery costs compressed gross margin. Its operating loss narrowed as spending fell; the larger improvement in its GAAP net loss also depended on a $48.2M investment-valuation gain, not operating profitability. Management is shifting software customers toward hosted subscriptions and seeking partners rather than independently funding further clinical expansion. For investors, the opportunity is a broader recurring-software base and valuable collaboration rights, while the immediate tests are customer expansion, collaboration economics, and clinical safety.

Key Financial Highlights

• Earnings quality: Equity-investment fair-value gains rose to $48.2M from $5.68M, principally reflecting Structure Therapeutics; they can reverse without a corresponding change in software or drug-discovery performance.
• Cash conversion: Accounts receivable fell $153M, substantially explaining positive OCF despite the net loss. Capital expenditures were $1.44M; deferred revenue declined $29.0M.
• Liquidity and obligations: Cash, cash equivalents, restricted cash, and marketable securities totaled $402M. Lease payments of $160M through 2037 and $82.0M of minimum payments under a three-year cloud agreement represent material future commitments.
• Software demand: Annual contract value, an operating metric rather than GAAP revenue, rose 4% to $199M; commercial net dollar retention fell to 100% from 113%. Deferred revenue declined to $192M from $221M, making renewed customer expansion important.
• Capital structure: Stock-based compensation was $43.0M; common shares outstanding rose ≈805,000 to 64.5M, while limited common shares were unchanged. No shares were sold under the at-the-market program in FY2025.

Business Developments

The mix is moving toward hosted software, whose revenue is recognized over time rather than largely upfront like on-premise licenses. Management expects the transition to weigh on near-term reported revenue even as it changes the business toward a less seasonal model. Hosted revenue reached $45.1M, while on-premise revenue slipped to $101M. All 20 of the largest pharmaceutical companies licensed the software; they represented 37% of software revenue, making large-customer expansion consequential.

Novartis paid $150M upfront in January 2025, and related collaboration revenue reached $30.0M for the year. Potential milestones across initial programs total $2.27B, but none had been recognized by year-end; Novartis controls later development and commercialization. Across the portfolio, Schrödinger had 20 active collaborative programs and potential royalties on 16, up from 13. These rights diversify possible future returns, but neither milestones nor royalties are contracted near-term earnings.

Management plans to complete ongoing Phase 1 studies of SGR-1505 and SGR-3515 while seeking partners to advance them, rather than independently initiating additional trials. That reduces prospective development spending but transfers more control over progress to partners. SGR-2921 was discontinued after two patient deaths were considered potentially drug-related. A restructuring and reduced independent clinical development are expected by management to save $70.0M annually in combination; those are prospective savings, not FY2025 earnings.

Risk Assessment

• Clinical safety and execution: The SGR-2921 discontinuation demonstrates that adverse events can terminate programs; SGR-1505 and SGR-3515 remain in early clinical testing with uncertain outcomes.
• Software growth and concentration: Commercial net dollar retention fell to 100%, one customer supplied 17% of FY2025 revenue, and lengthy sales cycles make expansion and contract timing consequential.
• Partner dependence: The $2.27B Novartis milestone opportunity depends on discoveries and subsequent decisions outside Schrödinger’s full control; no associated milestone revenue had been recognized.
• Sustained losses and funding: The $167M operating loss and $629M accumulated deficit could require financing if spending or collaboration receipts depart from management’s assumptions, despite its expectation of at least 24 months of funding.
• Revenue and valuation judgments: Collaboration revenue depends partly on estimates of work completed, while investment mark-to-market gains can materially alter GAAP earnings without improving operations.
• Intellectual property and cybersecurity: Licensed technology, sensitive research data, and hosted systems expose software adoption and partnerships to disputes, breaches, or outages.

Strategic Outlook and Investor Actionables

Schrödinger is trying to pair a more recurring software model with partner-funded drug development. The investment case improves if hosted growth produces renewed customer expansion and collaboration receipts become durable economics; it weakens if costs stay ahead of revenue or clinical setbacks limit partnering.

• Software: Monitor hosted revenue, annual contract value, and commercial net dollar retention; sustained expansion above 100% would support the transition despite near-term revenue-timing pressure.
• Collaboration economics: Monitor recognized milestones and drug-discovery gross profit; progress must translate into revenue that exceeds delivery costs.
• Clinical and cash discipline: Monitor initial SGR-3515 data expected in Q2 2026, SGR-1505 progress, partnering agreements, and OCF excluding unusually large receivables collections.